News | EP Lab | August 03, 2021

Biosense Webster Showcases New Data and Latest Innovations at Heart Rhythm 2021

Late-breaking results from first-in-human clinical experience of NuVision 4D ICE Ultrasound Catheter presented

The new Octaray high-density mapping catheter from Biosense Webster has 48 electrodes to enable faster and more detailed electromapping of the heart to better guide ablation procedures.

The new Octaray high-density mapping catheter from Biosense Webster has 48 electrodes to enable faster and more detailed electromapping of the heart to better guide ablation procedures. Photo by Dave Fornell


August 3, 2021 – Biosense Webster, the global leader in cardiac arrhythmia treatment and part of Johnson & Johnson Medical Devices Companies, announced today that data from 16 company sponsored studies will be presented at Heart Rhythm 2021, the Heart Rhythm Society (HRS) annual meeting. The data presented reflects Biosense Webster’s continued innovation and commitment to advancing science in the field of electrophysiology with the goal of improving patient outcomes.

Presentation topics included new data on novel technologies spanning Carto mapping technology, diagnostic catheters, therapeutic catheters, and the role of digital technologies in advancing cardiac arrhythmia treatment. Additionally, two abstracts will be presented highlighting real-world data on atrial fibrillation treatment outcomes.

As part of the Biosense Webster booth, a variety of interactive experiences will be available including hands-on demonstrations of the new Octaray high density mapping catheter with TRUEref Technology, CartoNet cloud-based software solution, and NuVision Ultrasound Catheter with imaging support from GE Healthcare Vivid Ultra Edition ultrasound systems.

For more information about Biosense Webster’s presence at Heart Rhythm 2021: www.BiosenseWebsterHRS.com

For more information: www.biosensewebster.com

VIDEO: EP Trends and New Technology From Biosense Webster at HRS 2021

Related Content

News | EP Lab

November 22, 2021 — BioSig Technologies Inc., a medical technology company commercializing an innovative biomedical ...

Home November 22, 2021
Home
Videos | EP Lab

Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz ...

Home November 22, 2021
Home
Feature | EP Lab

November 18, 2021 — The U.S. Food and Drug Administration (FDA) is reminding providers about the risk of major ...

Home November 18, 2021
Home
News | EP Lab

November 16, 2021 — Acutus Medical Inc. (Acutus), an arrhythmia management company focused on improving the way cardiac ...

Home November 16, 2021
Home
News | EP Lab

November 15, 2021 — Vektor Medical Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Home November 15, 2021
Home
Feature | EP Lab | By Arnaud Rosier, M.D.

With 1.2 to 1.4 million new electrophysiology (EP) devices being prescribed to patients around the world each year ...

Home October 28, 2021
Home
News | EP Lab

October 28, 2021 — CathVision, a medical technology company developing electrophysiology (EP) solutions in EP recording ...

Home October 28, 2021
Home
News | EP Lab

October 6, 2021 – Biosense Webster announced the first cases using a radiofrequency balloon ablation catheter were ...

Home October 06, 2021
Home
News | EP Lab
October 1, 2021 — The European Society of Cardiology (ESC) guidelines on cardiac pacing and cardiac resynchronization ...
Home October 04, 2021
Home
Videos | EP Lab
Khaldoun Tarakji, M.D., MPH, associate section head, cardiac electrophysiology, Heart and Vascular Institute at ...
Home October 04, 2021
Home
Subscribe Now